{"id":3164,"date":"2014-09-19T06:30:00","date_gmt":"2014-09-19T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-receives-horizon-2020-funding\/"},"modified":"2014-09-19T06:30:00","modified_gmt":"2014-09-19T06:30:00","slug":"xvivo-receives-horizon-2020-funding","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-receives-horizon-2020-funding\/","title":{"rendered":"XVIVO receives Horizon 2020 funding"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong>The European Commission has selected XVIVO Perfusion\u2019s project \u201cBiomarkers for clinical assessment of lungs intended for transplantation\u201d for funding through the Research and Innovation Framework Program Horizon 2020.<\/strong><\/div>\n<\/p>\n<p><span><span>A total of 2,666 proposals were submitted to the first SME (Small Medium Enterprises) Instrument Calls within the European Commission\u00b4s newly established Research and Innovation Framework Program Horizon 2020. 155 projects from 21 countries were selected for funding of a phase I feasibility study. Each project receives \u20ac50,000 to perform a feasibility study and to prepare a Phase 2 application, which, if granted, may result in additional funding.<\/span><\/span><\/p>\n<\/p>\n<p><span><span>\u201cWith a success rate of 6 percent, we are pleased to have been selected in competition with many other highly qualified companies. The focus is now on reaching the targets set for phase 1 and on preparing for a clinical trial in project phase 2,\u201d says Mrs Petra Apell, Regional Manager at XVIVO Perfusion. <\/span><\/span><\/p>\n<\/p>\n<p><span><span>The goal of the project is to identify biomarkers and medical device products that can further improve the evaluation of lungs using Ex Vivo Lung Perfusion (EVLP). Lung transplantation is the only therapeutic option for selected patients suffering from end-stage lung diseases. 80 percent of all donated lungs are not used for transplantation. The main reason is uncertainty regarding the function and quality of the lung. EVLP is a technique used to assess the quality of donated lungs prior to transplantation. EVLP could potentially lead to an increase in the utilization rate of donated lungs from today\u00b4s 20 percent to 40-60 percent. Validated and objective parameters to evaluate lung functions during EVLP are expected to improve clinical outcomes in lung transplantation after EVLP.<\/span><\/span><\/p>\n<\/p>\n<p><span><span>\u201cWe are delighted that the European Commission has decided to support this project financially. New biomarkers may lead to continued development and expansion of the organ perfusion market,\u201d says Dr Magnus Nilsson, CEO of XVIVO Perfusion.<\/span><\/span><\/p>\n<p><span><span>September 19, 2014<br \/> Gothenburg<br \/> XVIVO Perfusion AB (publ)<br \/> Magnus Nilsson <br \/> CEO<\/span><\/span><\/p>\n<div class=\"mfn-footer\">\n<p><span>For further information please contact:<br \/><\/span><br \/><span>Christoffer Rosenblad, CFO, +46 31\u00a0788 21 59, <a href=\"mailto:christoffer.rosenblad@xvivoperfusion.com\" rel=\"nofollow\">christoffer.rosenblad@xvivoperfusion.com<\/a><\/span><br \/><span>For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, <a href=\"http:\/\/www.xvivoperfusion.com\" rel=\"nofollow\">www.xvivoperfusion.com<\/a><\/span><\/p>\n<p><span>The information was submitted for publication on\u00a0September 19, 2014\u00a0at 8:30 a.m.<\/span><\/p>\n<p><span>This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The European Commission has selected XVIVO Perfusion\u2019s project \u201cBiomarkers for clinical assessment of lungs intended for transplantation\u201d for funding through&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-3164","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-listing","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other","mfn-news-tag-mfn"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>XVIVO receives Horizon 2020 funding - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-receives-horizon-2020-funding\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO receives Horizon 2020 funding - XVIVO\" \/>\n<meta property=\"og:description\" content=\"The European Commission has selected XVIVO Perfusion\u2019s project \u201cBiomarkers for clinical assessment of lungs intended for transplantation\u201d for funding through...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-receives-horizon-2020-funding\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-receives-horizon-2020-funding\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-receives-horizon-2020-funding\\\/\",\"name\":\"XVIVO receives Horizon 2020 funding - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2014-09-19T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-receives-horizon-2020-funding\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-receives-horizon-2020-funding\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-receives-horizon-2020-funding\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO receives Horizon 2020 funding\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO receives Horizon 2020 funding - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-receives-horizon-2020-funding\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO receives Horizon 2020 funding - XVIVO","og_description":"The European Commission has selected XVIVO Perfusion\u2019s project \u201cBiomarkers for clinical assessment of lungs intended for transplantation\u201d for funding through...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-receives-horizon-2020-funding\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-receives-horizon-2020-funding\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-receives-horizon-2020-funding\/","name":"XVIVO receives Horizon 2020 funding - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2014-09-19T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-receives-horizon-2020-funding\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-receives-horizon-2020-funding\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-receives-horizon-2020-funding\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO receives Horizon 2020 funding"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}